What is it about?

This is a counterpoint to the letter 2018.1276, whereby we explain the reasoning behind our difference of opinion in methods to establish acceptance limits for quality control testing for infectious disease serology

Featured Image

Read the Original

This page is a summary of: Counterpoint to the Letter to the Editor by Badrick and Parvin in regard to Comparison of four methods of establishing control limits for monitoring quality controls in infectious disease serology testing, Clinical Chemistry and Laboratory Medicine (CCLM), April 2019, De Gruyter,
DOI: 10.1515/cclm-2018-1321.
You can read the full text:

Read

Contributors

Be the first to contribute to this page